[Clinical trials of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Many different infections including urinary tract infections occur in the field of obstetrics and gynecology. Furthermore, in most cases, it is practically impossible to clearly identify causative organisms as in cases of pelvic peritonitis and parametritis. In many incidents, causative organisms consist mainly of Escherichia coli, and recently, Enterococcus faecalis, Bacteroides fragilis, Klebsiella pneumoniae, Pseudomonas aeruginosa, etc. have also been identified. Because the new antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791), is very effective against these bacteria, and because of its wide spectrum, we believe it is especially effective against infections of obstetrics and gynecology. The distribution of this antibiotic into various organs and tissues was similar to other drugs, and it reaches a high level in internal genital organs, hence it should be effective for the treatment of obstetric/gynecological infections. Its toxicity is low also, and no side effects nor abnormal laboratory findings were observed in our trials. Results of our trials are summarized below: Of 9 cases of obstetric/gynecological infections, the antibiotic showed excellent effectiveness against 2, good against 6, for the efficacy ratio of 89%. No side effects nor abnormal laboratory findings were observed.